New pill aims to slash hidden heart risk factor
NCT ID NCT06816264
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested an oral drug called HRS-5346 in 120 adults with high lipoprotein(a) levels and a high risk of cardiovascular events. The main goal was to see how well the drug lowers Lp(a) levels compared to a placebo, and to check its safety. The study is completed, and results will show if this drug could become a new option for managing this stubborn risk factor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-5346 (an oral drug to lower lipoprotein(a))
- What this could lead to
- If successful, this could lead to a new oral treatment to reduce high lipoprotein(a) levels, potentially lowering the risk of heart attacks and strokes in high-risk patients.
- What could go wrong
- This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. The drug may not work as hoped or could have side effects. Further larger studies are needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT OF LIPOPROTEIN DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100000, China